Krittiya MosikanonDumrongkiet ArthanAikkarach KettawanRungsunn TungtrongchitrPattaneeya PrangthipMahidol University2018-12-212019-03-142018-12-212019-03-142017-03-04Journal of Dietary Supplements. Vol.14, No.2 (2017), 173-1851939022X193902112-s2.0-84981524172https://repository.li.mahidol.ac.th/handle/20.500.14594/41552© 2016, Copyright © Taylor & Francis Group, LLC. Increased inflammation occurs with excessive adiposity and yeast β-glucan modulates immune responses. This study investigated the potential effect of yeast β-glucan on inflammatory cytokines in overweight/obese people. A randomized, double blinded, placebo-controlled, clinical trial design enrolled 44 overweight/obese participants with body mass index ≥23 kg/m2, randomized to two groups receiving β–glucan 477 mg/capsule (n = 22) or placebo (n = 22) orally for six weeks. At weeks one to two, participants received 1 β–glucan or placebo capsule/day and at four weeks two tablets/day. Anthropometric changes, lipid profiles, liver and renal functions, and inflammatory cytokines were measured. β-glucan reduced waist circumference (p = 0.037) and blood pressure (p = 0.006) compared with controls after six weeks of intervention. No statistical significance between groups was observed for triglyceride, cholesterol, lipid profile, liver and renal function, or energy and nutrient intake compared with controls at week six. β-glucan increased interlukin-10 (IL-10), an anti-inflammatory cytokine, by 23.97% from baseline at week two (p < 0.001) and 31.12% at week six (p < 0.001) and was significantly increased compared with controls at week two (p < 0.001) until week six (p < 0.001). β-glucan reduced pro-inflammatory cytokines IL-6 at week six (p = 0.005) and tumor necrosis factor-α at week two (p = 0.037) compared with controls. Supplementation of yeast β-glucan for six weeks modulated pro-cytokines that accelerate overweight/obese comorbidities and reduced blood pressure as well as waist circumference, the strong risk factors for cardiovascular disease, in overweight/obese subjects. Thus, β-glucan might have the potential to decrease comorbid conditions associated with overweight/ obesity.Mahidol UniversityAgricultural and Biological SciencesArticleSCOPUS10.1080/19390211.2016.1207005